Importantly, ablation of H19 in mice showed protection against MCT-induced PH features (RVSP, RV hypertrophy, pulmonary vessel medial wall thickness, and vessel muscularization), indicating that H19 could be a potential therapeutic target for PAH. This evidence concerns the gene H19 and pulmonary arterial hypertension.